SCHEMBL29975637

SCHEMBL29975637

Fc1ccc2ncc(Cl)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.43
BACE1 P56817 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
CNR1 P21554 4/20 0.40
PDGFRB P09619 2/20 0.39
PDGFRA P16234 2/20 0.39
KCNH2 Q12809 1/20 0.38
AMY1A P0DUB6 2/20 0.38
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 1/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
ALPG P10696 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2A6 P11509 1/20 0.35
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3868339 0.83 BACE1 (0.47) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL16155308 0.76 ALDH1A1 (0.50) BACE1PDE3BPDE3ALMNAKDM4E
SCHEMBL7879181 0.76 BACE1 (0.46) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL1359776 0.76 MAP4K4 (0.46) PDE3BPDE3APDGFRBPDGFRAKMT2A
SCHEMBL845999 0.76 BACE1 (0.50) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL584342 0.76 BACE1 (0.41) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL12686649 0.76 CYP1A2 (0.57) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL4142083 0.76 MET (0.38) PDE3BPDE3ALMNAKMT2AALPL
SCHEMBL21988901 0.76 MAP4K4 (0.54) BACE1PDE3BPDE3APDGFRBPDGFRA
SCHEMBL16289408 0.76 BACE1 (0.41) BACE1PDE3BPDE3APDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2022-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 CNR2 3473/4885BACE1 1210/4885PDE3B 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.